Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Patent
1996-04-15
1999-02-16
Kemmerer, Elizabeth
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
435 72, 435 697, 4351723, 436501, C12Q 125, G01N 3353
Patent
active
058719342
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
This invention relates to drug binding proteins, to genes encoding same and to assays and methods for screening pharmaceuticals. More specifically, this invention relates to Cytokine Suppressive Anti-Inflammatory Drug (CSAID) binding proteins, to genes encoding same and to assays and screens useful in the evaluation and characterization of drugs of this pharmacologic class.
BACKGROUND OF THE INVENTION
Cytokines play an important role in regulating the cellular response during inflammation and other immune functions. Of particular interest are the cytokines interleukin-1 (IL-1, .alpha. and .beta.) and tumor necrosis factor (TNF, .alpha. and .beta.), which are the intercellular proteins involved in the initial step of the inflammatory response cascade (Arai, et al., Ann. Rev. Biochem. 59: 783-836 (1990)). Thus, there has been a substantial amount of research recently devoted to interfering with the production of IL-1 and TNF in response to an inflammatory stimulus.
One therapeutic approach involves suppressing the production of IL-1 and TNF at the level of transcription and/or translation and/or secretion. The activities associated with certain of pyridinyl imidazoles led to a class of compounds referred to as "CSAIDs", or Cytokine suppressing Anti-Inflammatory Drugs (FIG. 1). These compounds appear to arrest the expression of IL-1 and TNF predominantly at the translational level, although a lesser effect on transcription has also been observed but effects on other steps cannot be ruled out.
The pyridinyl imidazole, 5-(4-pyridyl)-6(4-fluorophenyl)-2,3-dihydroimidazo(2,1-b)thiazole (SK&F 86002) was identified as the prototypic CSAID. The basis for its activity has been established and characterized (Lee, et al., Int'l. J. Immunopharm. 10(7): 835-843 (1988); Agents and Actions 27(3/4): 277-279 (1989) and Int'l. J. Immunother. 6(1):1-12 (1990)). SAR studies (discussed herein) suggest that cytokine suppressive effect of the pyridinyl imidazoles represents a unique activity independent of their inhibitory effects on eicosanoid and leukotriene production. However, no compound of the initial series was selective for cytokine suppressive activity or was particularly potent.
Since the CSAIDs have substantial potential as novel anti-inflammatory therapeutic agents, there is significant interest in characterizing their mechanism of action at the molecular level, as well as obtaining compounds with increased selectivity and potency. Specifically, identification and characterization of the CSAID molecular target would enhance the understanding of the biochemical processes involved in inflammation and aid in the design and screening of more potent anti-inflammatory drugs. This invention discloses, inter alia, the purification and characterization of such CSAID binding proteins (CSBPs).
The DNAs of this invention, such as the specific sequences disclosed herein, are useful in that they encode the genetic information required for the expression of the novel CSBPs. Additionally, the sequences may be used as probes in order to isolate and identify any additional members of the CSBP family as well as forming the basis of antisense therapy for disease conditions which are characterized by atypical expression of the CSBP gene. The novel protein itself is useful directly as a therapeutic or diagnostic agent as well as a component in a screening system for compounds which are antagonists or agonists of CSAID binding activity. The protein is also useful for eliciting antibody production in heterologous species, said antibodies being useful for the aforesaid diagnostic, therapeutic and screening applications. These and additional uses for the reagents described herein will become apparent to those of ordinary skill in the art upon reading this specification.
BRIEF DESCRIPTION OF THE INVENTION
This invention provides isolated nucleic acid molecules encoding a CSAID binding protein, including mRNAs, DNAs, cDNAs as well as antisense analogs thereof and biologically active and diagnostically or therapeutica
REFERENCES:
patent: 5512473 (1996-04-01), Brent et al.
patent: 5593992 (1997-01-01), Adams et al.
Payne, et al., "Identification of the regulatory phosphorylation sites in pp42/mitogen-activated protein kinase (MAP kinase)," EMBO J. 10: 885-892, (1991).
Boulton, et al., "ERKs: A Family of Protein-Serine/Threonine Kinases That Are Activated and Tyrosine Phosphorylated in Response to Insulin and NGF," Cell 65: 663-675 (1991).
Lee, et al., "Inhibition Of Human Monocyte Il-1 Production By SK&F 86002," Int. J. Immunother. 6: 1-12 (1990).
Griswold, et al., "Differentiation In Vivo Of Classical Non-Steroidal Antinflammatory Drugs From Cytokine Suppressive Antinflammatory Drugs And Other Pharmacological Classes Using Mouse Tumour Necrosis Factor Alpha Production," Drugs Exptl. Clin. Res. 19: 243-248 (1993).
Cuenda, et al., "SB 203580 is a specific inhibitor of a MAP kinanse homologue which is stimulated by cellular stresses and interleukin-1," FEBS Letters, 364: pp. 229-233 (1995).
Lee, et al., "A protein kinase involved in the regulation of inflammatory cytokine biosynthesis," Nature, 372: 22/29, pp. 739-746 (1994).
Ershler, et al., "Novel CDC2-related protein kinases produced in murine hematopoietic stem cells," Gene, 124: pp. 305-306 (1993).
Young, et al., "Pyridinyl imidazoles inhibit IL-y and TNF production at the protein level," Agents Actions, Special Conference Issue 39, pp. C67-C69 (1993).
Han, et al., "A MAP Kinase Targeted by Endotoxin and Hyperosmolarity in Mammalian Cells," Science, 265: pp. 808-811 (1994).
Lee, et al., "Inhibition Of Monocyte Il-1 Production By The Anti-Inflammatory Compound, SK&F 86002," Int. J. Immunopharmac. 10:(7), pp. 835-843 (1988).
Hen et al. Biochimica et Biophysica Acta 1265:224-227, 1995.
Rouse et al. Cell 78:1027-1037, 1994.
Callard et al. The Cytokine FactsBook, Academic Press Limited, San Diego, p. 31., 1994.
Bowie et al. Science 247:1306-1310, 1990.
Ngo et al. The Protein Folding Problem and Teriary Structure Prediction, Merz et al., eds., Birkhauser, Boston, pp. 491-495, 1994.
Wells. Biochemistry 29:8509-8517, 1990.
George et al. pp. 127-149 in: Macromolecular Sequencing and Synthesis: Selected Methods and Applications, ed., D.H. Schlesinger, Alan R. Liss, Inc., New York, 1988.
Adams Jerry Leroy
Gallagher Timothy Francis
Green David W.
Heys John Richard
Lee John Cheung-Lun
Hecht Elizabeth J.
Kemmerer Elizabeth
King William T.
SmithKline Beecham Corporation
LandOfFree
Screening methods using cytokine suppressive anti-inflammatory d does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Screening methods using cytokine suppressive anti-inflammatory d, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Screening methods using cytokine suppressive anti-inflammatory d will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2061191